60 withdrawn. 60 Phase 2, 13 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 60 | Withdrawn 60 |
| Phase 1 | 13 | Withdrawn 13 |
| Phase 3 | 1 | Withdrawn 1 |
Follow Nervous System Neoplasms: new trials by email Literature Review of Nervous System Neoplasms trials Research Report on Nervous System Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of ONC201 for Refractory Meningioma ONC201 - Meningioma, Refractory Meningioma | Phase 2 | Withdrawn | University of Nebraska | 2026-12-01 | 2026-01-26 | |
| Direct Comparison of Ga-68-DOTATATE and Ga-68-DOTATOC Ga-68- DOTATATE, Ga-68-DOTATOC - Meningioma | Phase 2 | Withdrawn | Weill Medical College of Cornell University | 2026-08-01 | 2026-08-31 | |
| A Phase II Clinical Study of Utidelone and Bevacizumab With or Without Etoposide in Patients With Brain Metastases From Malignant Solid Tumors Utidelone, Bevacizumab - Malignant Solid Tumor, Brain Metastasis | Phase 2 | Withdrawn | Tianjin Medical University Cancer Institute and Hospital | 2026-05-01 | 2026-07-16 | |
| HSV G207 With a Single Radiation Dose in Children With Recurrent High-Grade Glioma Biological G207 - Neoplasms, High Grade Glioma | Phase 2 | Withdrawn | Pediatric Brain Tumor Consortium | 2025-09-01 | 2026-02-10 | |
| A Window of Opportunity Study of Patritumab Deruxtecan in Patients With Brain Metastases Patritumab deruxtecan - Brain Metastases, Adult | Phase 2 | Withdrawn | Mustafa Khasraw, MBChB, MD, FRCP, FRACP | 2025-07-01 | 2025-06-15 | |
| Study of Lenvatinib Plus Pembrolizumab in IO Refractory mRCC Patients With Brain Metastases Pembrolizumab, Lenvatinib - Renal Cell Carcinoma, Brain Metastasis | Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2025-06-04 | 2025-08-13 | |
| Cemiplimab for the Treatment of Untreated Brain Metastases From PD-L1 >= 50% Non-Small Cell Lung Cancer Biospecimen Collection, Cemiplimab, Computed Tomography - Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain | Phase 2 | Withdrawn | City of Hope Medical Center | 2025-04-15 | 2025-05-26 | |
| JDQ443 for KRAS G12C NSCLC Brain Metastases JDQ443 - Non Small Cell Lung Cancer Metastatic, Brain Metastases, Adult | Phase 2 | Withdrawn | Maastricht University Medical Center | 2024-04-15 | 2024-05-29 | |
| Selumetinib in Chinese Paediatric With Post-operative NF1-PNs, Phaseâ…¡, Double-Blinded, Placebo-Controlled Study Selumetinib, Placebo - Neurofibromatosis Type 1, Plexiform Neurofibromas | Phase 2 | Withdrawn | AstraZeneca | 2023-08-31 | 2023-08-14 | |
| Combination Liposomal Irinotecan and Pembrolizumab For Triple-Negative Breast Cancer (TNBC) With Brain Metastases (BM) Pembrolizumab, Liposomal Irinotecan - Triple Negative Breast Cancer, Brain Metastases | Phase 2 | Withdrawn | Washington University School of Medicine | 2023-07-31 | 2023-07-11 | |
| SRS Timing With Immune Checkpoint Inhibition in Patients With Untreated Brain Metastases From Non-small Cell Lung Cancer Stereotactic Radiosurgery, Immunotherapy - Brain Metastases, Non Small Cell Lung Cancer | Phase 2 | Withdrawn | Duke University | 2023-03-01 | 2023-03-02 | |
| 177Lu-DTPA-Omburtamab Radioimmunotherapy for Leptomeningeal Metastasis From Solid Tumors (Breast, NSCLC, Malignant Melanoma) radiolabeled DPTA-omburtamab - Leptomeningeal Metastasis, Solid Tumor, Adult | Phase 1 / Phase 2 | Withdrawn | Y-mAbs Therapeutics | 2022-08-31 | 2022-07-15 | |
| TOPAZ: Tucatinib in COmbination With Pembrolizumab And TrastuZumab in Patients With HER2-Positive Breast Cancer Brain Metastases Tucatinib, Pembrolizumab, Trastuzumab - Breast Cancer, Brain Metastases | Phase 1 / Phase 2 | Withdrawn | Reva Basho | 2022-06-01 | 2022-07-01 | |
| Tranexamic Acid for Blood Loss Minimization in Endoscopic Pituitary Surgery Tranexamic acid, Placebo - Pituitary Tumor, Blood Loss | Phase 2 | Withdrawn | University of North Carolina, Chapel Hill | 2022-03-01 | 2022-04-05 | |
| Study of ALXN1830 Administered Subcutaneously in Adults With Generalized Myasthenia Gravis ALXN1830, Placebo - Generalized Myasthenia Gravis | Phase 2 | Withdrawn | Alexion Pharmaceuticals, Inc. | 2022-01-01 | 2022-02-11 | |
| Evaluation of Neratinib for Treatment and Prevention of Subsequent CNS Event(s) in Patients With Brain Metastasis of Advanced HER2 Positive Breast Cancer Neratinib - Breast Cancer, Brain Metastases | Phase 2 | Withdrawn | Jules Bordet Institute | 2021-11-24 | 2022-03-02 | |
| Study With Infigratinib in Subjects With Advanced Solid and CNS Tumors or Recurrent or Progressive Low-Grade Glioma With Selected FGFR1-3 Alterations Infigratinib - Advanced Solid Tumor, CNS Tumor | Phase 1 / Phase 2 | Withdrawn | Helsinn Healthcare SA | 2021-10-01 | 2023-02-23 | |
| 18F-Fluciclovine PET and Multiparametric MR Imaging PET/CT with F-Fluciclovine (Axumin) - Brain Tumor, Recurrent, Adult | Phase 2 | Withdrawn | Loma Linda University | 2020-08-24 | 2024-09-03 | |
| Single vs Multi-fraction SRS Patients on Immunotherapy Radiosurgery Single Treatment, Radiosurgery Three Treatments - Brain Cancer, Brain Metastases | Phase 2 | Withdrawn | University of Chicago | 2020-06-29 | 2023-08-28 | |
| Combination of PVSRIPO and Atezolizumab for Adults With Recurrent Malignant Glioma PVSRIPO, Atezolizumab - Malignant Glioma | Phase 1 / Phase 2 | Withdrawn | Darell Bigner | 2020-02-01 | 2020-02-11 |
Showing 20 of 60. Sign in to see all of them.
Brain Neoplasms (35) · Glioblastoma (13) · Central Nervous System Neoplasms (11) · Glioma (8) · Gliosarcoma (8) · Breast Neoplasms (6) · Carcinoma, Non-Small-Cell Lung (6) · Pituitary Neoplasms (5) · Neoplasm Metastasis (4) · Astrocytoma (3) · Meningioma (3) · Neoplasms (3) · Neurofibroma, Plexiform (3) · Oligodendroglioma (3) · Growth Hormone-Secreting Pituitary Adenoma (2)
Nervous System Diseases (60) · Neoplasms (57) · Neoplasms by Site (57) · Brain Diseases (43) · Central Nervous System Neoplasms (43) · Central Nervous System Diseases (42) · Neoplasms by Histologic Type (30) · Neoplasms, Nerve Tissue (27) · Neoplasms, Germ Cell and Embryonal (22) · Neuroectodermal Tumors (22) · Neoplasms, Glandular and Epithelial (21) · Neoplasms, Neuroepithelial (17) · Astrocytoma (10) · Skin Diseases (10)
Temozolomide (8) · Carboplatin (4) · Magnetic Resonance Spectroscopy (4) · Bevacizumab (3) · Carmustine (3) · Methotrexate (3) · Radiotherapy (3) · pembrolizumab (3) · AZD 6244 (2) · Aminolevulinic Acid (2) · Filgrastim (2) · Radiosurgery (2) · Thiotepa (2) · Trastuzumab (2) · cabazitaxel (2)
M.D. Anderson Cancer Center (4) · Duke University (2) · Jonsson Comprehensive Cancer Center (2) · Jules Bordet Institute (2) · NYU Langone Health (2) · National Cancer Institute (NCI) (2) · OHSU Knight Cancer Institute (2) · Pediatric Brain Tumor Consortium (2) · University of Texas Southwestern Medical Center (2) · Alexion Pharmaceuticals, Inc. (1) · AstraZeneca (1) · Barbara Ann Karmanos Cancer Institute (1) · Barretos Cancer Hospital (1) · Burzynski Research Institute (1) · Children's National Research Institute (1)
United States (30) · Belgium (2) · Canada (2) · Argentina (1) · Brazil (1) · France (1) · Germany (1) · United Kingdom (1)
Jonathan L. Finlay, MB, ChB (2) · Vinay K. Puduvalli, MD (2) · Ahmad Awada, MD, PhD (1) · Anthony Heaney, MD (1) · Anuradha Banerjee, MD (1) · Arya Amini (1) · Ashley Frith, M.D. (1) · Brent Senior, MD (1) · Brigitte C Widemann, M.D. (1) · Bruce Wallin, MD (1) · Camilo Jimenez (1) · Carl Koschmann, MD (1) · Costas Hadjipanayis, MD, PhD (1) · Darell D Bigner, MD, PhD (1) · Dina M Randazzo, DO (1)
2017 (1), 2018 (1), 2023 (1), P30CA016058 (1), P30CA022453 (1), P30CA033572 (1), P30CA072720 (1), P30CA093373 (1), R01CA167632 (1), R01CA176659 (1), R21CA186169 (1), UM1CA081457 (1), UM1CA186704 (1)